Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ginkgo Bioworks Holdings Inc (DNA) vs Annaly Capital Management, Inc. (NLY) Price & Performance

Ginkgo Bioworks Holdings IncTrade
Annaly Capital Management, Inc.Trade

Price performance (Past 24H)

Key statistics

Ginkgo Bioworks Holdings Inc vs Annaly Capital Management, Inc. — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.34 (market cap $505.73M), while Annaly Capital Management, Inc. trades at $23.26 (market cap $17.44B). The key difference: Annaly Capital Management, Inc. is far larger — about 34.5× Ginkgo Bioworks Holdings Inc's market cap, and Annaly Capital Management, Inc. pays a 12.96% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.

DNANLY
Market Cap
$505.73M$17.44B
Sector
HealthFinancials
52-Week High
$16.14$24.40
52-Week Low
$5.48$20.21
Enterprise Value
$607.68M
Dividend Yield
12.96%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.

DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.

Annaly Capital Management, Inc.

NLY trades at $22.91, down 0.56% today, with strong technical momentum showing a bullish moving average signal. The stock demonstrates robust fundamentals with a P/E of 5.59, ROE of 20.66%, and consistent earnings beats in recent quarters. Recent Q2 2026 results exceeded expectations with $0.79 EPS versus $0.75 estimate, supported by growing net interest income and dividend coverage improvements.

Analyst consensus remains positive with a $24.50 price target and 57% buy ratings, though investors should monitor interest rate sensitivity given the REIT's mortgage-focused business model. The 13%+ dividend yield provides income appeal, but funding costs and mortgage market volatility present ongoing risks to book value stability.

Returns comparison

Trailing returns across standard periods

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA

About Annaly Capital Management, Inc.

Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.

Read more on NLY